Meeting
2020 ASCO Virtual Scientific Program
Bortezomib, lenalidomide, and dexamethasone (VRD) is superior to lenalidomide, adriamycin, and dexamethasone (RAD) prior to risk-adapted transplant in newly diagnosed myeloma.
Authors
Stefan Knop
Medizinische Klinik und Poliklinik II, Julius Maximilians Universität Würzburg, Würzburg, Germany
Stefan Knop , Christian Langer , Monika Martha Engelhardt , Florian Bassermann , Martin Schreder , Lars-Olof Muegge , Kerstin Schaefer-Eckart , Igor W. Blau , Denise Wolleschak , Julia Reusch , Ivana von Metzler , Bernd Metzner , Tobias Dechow , Bernd Hertenstein , Heinz Duerk , Sebastian Theurich , Thomas Stuebig , Jan Kroenke , Swantje Held , Hermann Einsele
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Plasma Cell Dyscrasia
Track
Hematologic Malignancies
Sub Track
Cell Therapy, Bispecific Antibodies, and Autologous Stem Cell Transplantation for Plasma Cell Disorders
Clinical Trial Registration Number
NCT01685814
Citation
J Clin Oncol 38: 2020 (suppl; abstr 8521)
DOI
10.1200/JCO.2020.38.15_suppl.8521
Abstract #
8521
Poster Bd #
421
Abstract Disclosures
Similar Posters
First Author: George Somlo
Poster
2014 ASCO Annual Meeting
Optimizing induction and pretransplant consolidation for myeloma: Results of Myeloma XI, a phase III trial comparing different IMiDs.
First Author: Charlotte Pawlyn
Poster
2013 ASCO Annual Meeting
Clinical outcomes after intensive VDT-PACE therapy for relapsed multiple myeloma.
First Author: Preet Paul Singh
Poster
2023 ASCO Annual Meeting
Curability of multiple myeloma (MM) based on relative survival rate (RSR) in patients (pts) treated on earlier total therapy (TT) protocols.
First Author: Samer Al Hadidi